

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/500,968	05/04/2005	Vincent Goffin	255563US0PCT	1164	
22850 7599 10/20/2008 OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, P.C. 1940 DUKE STREET			EXAM	EXAMINER	
			SAOUD, CHRISTINE J		
ALEXANDRIA, VA 22314			ART UNIT	PAPER NUMBER	
			1647		
			NOTIFICATION DATE	DELIVERY MODE	
			10/20/2008	EI ECTRONIC	

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com oblonpat@oblon.com jgardner@oblon.com

## Application No. Applicant(s) 10/500 968 GOFFIN ET AL. Office Action Summary Examiner Art Unit Christine J. Saoud 1647 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 01 July 2008. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-20 is/are pending in the application. 4a) Of the above claim(s) 10-12 and 20 is/are withdrawn from consideration. 5) Claim(s) \_\_\_\_\_ is/are allowed. 6) Claim(s) 1-9 and 13-19 is/are rejected. 7) Claim(s) \_\_\_\_\_ is/are objected to. 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some \* c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \* See the attached detailed Office action for a list of the certified copies not received.

PTOL-326 (Rev. 08-06)

1) Notice of References Cited (PTO-892)

3) Information Disclosure Statement(s) (PTC/G5/08)
Paper No(s)/Mail Date \_\_\_\_\_\_

Notice of Draftsperson's Patent Drawing Review (PTO-948)

Attachment(s)

Interview Summary (PTO-413)
 Paper No(s)/Mail Date.

6) Other:

Notice of Informal Patent Application

Application/Control Number: 10/500,968 Page 2

Art Unit: 1647

## DETAILED ACTION

Claims 1-12 have been amended and claims 13-20 have been added in the amendment filed 01 July 2008. Claims 1-20 are pending in the instant application.

Claims 10-12 and 20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventin, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 06 December 2007. Claim 12 has been amended such that it is now directed to a method of preventing or treating a disease or disorder, which is a different invention from what was previously examined/presented. The claim was previously directed to use for obtaining a therapeutic composition, which was interpreted as a method of making a therapeutic composition. Therefore, claim 12 is now withdrawn from further consideration as it is directed to a distinct invention from what was previously examined.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Any objection or rejection of record which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.

Applicant's arguments filed 01 July 2008 have been fully considered, but are not found persuasive.

### Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

Application/Control Number: 10/500,968

Art Unit: 1647

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-9, 13-19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention for the reasons of record as applied to claims 1-5 in the previous Office action.

The claims recite various numbered amino acid positions, such as "Cys<sub>4</sub>" and "Cys<sub>11</sub>". There is insufficient antecedent basis for these limitations in the claims. Reference to a particular amino acid position requires reference to a particular amino acid sequence, therefore, the claim lacks antecedent basis for the positions which are being recited. While the Office acknowledges that Applicant will not want to be bound to a specific sequence, some sort of reference to a sequence will be necessary. Applicant may want to review the specification for basis of using a particular sequence as a reference and using some sort of "corresponding to" recitation. The Office has not reviewed the specification for support or basis of this kind of language.

Claims 1-9 and 13-19 are indefinite and unclear for the recitation of particular amino acid positions for cysteine for the reasons provided above, as well as for the recitation of particular N-terminal amino acids. The metes and bounds of the claims cannot be determined, because without some reference to a base structure which is the starting point for making mutations, one of ordinary skill in the art cannot determine what is encompassed or intended by the claims. The claims are broadly directed to mammalian prolactin variants, however, not all mammalian prolactin molecules have the same amino acid sequence structure.

Application/Control Number: 10/500,968

Art Unit: 1647

For example, U.S. Pat. No. 4,767,709 depicts the amino acid sequence for bovine prolactin in Figure 3, however, there appears to be an N-terminal signal sequence. The instant claims do not indicate if numbering of positions begins at the N-terminus with or without the signal sequence. This figure also does not show cysteine residues that would correspond to a position 4 and 11 - rather they would correspond to possibly positions 4 and 12. Furthermore, the claims recite "binding site 2 of prolactin", however, the metes and bounds of this are not clear. Would one of ordinary skill in the art at the time the invention was made recognize which amino acid positions of prolactin (of any prolactin) are included by the phrase "binding site 2"?

Applicant only states that the rejection is now moot. Applicant's assertion is not found persuasive as the amendment to the claims has not obviate the grounds of rejection as set forth above.

### Conclusion

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire

THREE MONTHS from the mailing date of this action. In the event a first reply is
filed within TWO MONTHS of the mailing date of this final action and the advisory

Application/Control Number: 10/500,968

Art Unit: 1647

action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christine J. Saoud whose telephone number is 571-272-0891. The examiner can normally be reached on Monday-Friday, 6AM-2PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath Rao can be reached on 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/500,968 Page 6

Art Unit: 1647

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Christine J Saoud/ Primary Examiner, Art Unit 1647